Majority of Indian districts face high heatwave risk, study shows
NEW DELHI, May 20 (Reuters) - Nearly 60% of Indian districts, home to three-quarters of the population, face a "high to very high" risk from extreme heat, with rising night-time temperatures and humidity compounding the health impact, a study has found.
The report, published on Tuesday by the New Delhi-based Council on Energy, Environment and Water (CEEW) think tank, analysed climate, health, and infrastructure data to calculate a heat-risk score.
"About 57 per cent of Indian districts, home to 76 per cent of India's total population, are currently at high to very high heat risk," the study found, with the heat risk in the capital New Delhi among the highest.
The study comes as some parts of north India continue to grapple with heatwave and severe heatwave conditions. Billions of people across South Asia grapple with soaring temperatures each year, a trend scientists say has been exacerbated by human-driven climate change.
The study also flagged a rise in relative humidity across north India, including in traditionally arid regions, which worsens heat stress on the human body by slowing the process of sweating and making it harder to release heat as temperatures soar.
Factoring in more dimensions like humidity and demographics in heat risk planning, and creating a national repository of heat action plans for cross-learning between states are among the measures the study recommends to "bridge the heat resilience gap".
India recorded more than 40,000 suspected heatstroke cases and at least 110 confirmed deaths between March 1 and June 18 last year, when its northwestern and eastern parts recorded more than twice the usual number of heatwave days.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Sun
5 hours ago
- The Sun
Major boost to NHS as robotic surgery will slash stubbornly high waiting lists – but it'll take a decade
ROBOTIC surgery will slash waiting lists in a decade, the head of the NHS will say today. NHS England estimates robotic systems will be used in half a million operations a year by 2035, compared with 70,000 last year. That will include nine out of ten keyhole ops in the gut and pelvis, and increasing numbers of emergency surgeries. Health service boss Sir Jim Mackey will say at an NHS conference today: 'We have pledged to return to shorter elective waiting times by 2029 and we are using every tool at our disposal. 'Robotic surgery will play a huge part in this. 'Not only does it speed up the number of procedures the NHS can do, but it also means better outcomes, faster recoveries and shorter hospital stays.' Waiting lists in England are stubbornly high at 7.4million. The total increased in March as demand soared at a time of staff and cash shortages. Robot-assisted surgery uses super-precise mechanical arms that are electronically controlled by a surgeon and do internal operating work through tiny incisions on the body. They can be used for many common operations including hernia repairs, organ removals, hip and knee replacements and cancer treatment. Patients often have less blood loss, less scarring and need less anaesthetic, helping them recover faster. More than 140 robots are already in use across the UK. The NHS spending watchdog Nice recently approved 11 machines for use in England in the hope it will end a postcode lottery in their use.
BBC News
6 hours ago
- BBC News
TB: India brought forward its tuberculosis elimination deadline - but can it meet it?
Atul Kumar (name changed) anxiously paced the corridor of a public hospital in India's capital Delhi.A small-appliance mechanic, he was struggling to secure medicines for his 26-year-old daughter who suffers from drug-resistant tuberculosis (TB). Mr Kumar said his daughter needed 22 tablets of Monopas, an antibiotic used for treating TB, every day. "In the past 18 months, I haven't received government-supplied medicine for even two full months," he told BBC Hindi in January, months before India's declared deadline to eliminate the infectious to buy costly drugs from private pharmacies, Mr Kumar was drowning in debt. A week's supply cost 1,400 rupees ($16; £12), more than half his weekly income. After the BBC raised the issue, authorities supplied the medicines Mr Kumar's daughter needed. Federal Health Secretary Punya Salila Srivastava said that the government usually acts quickly to fix medicine access issues when Kumar's daughter is one of millions of Indians suffering from tuberculosis, a bacterial disease that infects the lungs and is spread when the infected person coughs or home to 27% of the world's tuberculosis cases, sees two TB-related deaths every three minutes. India's TB burden has long been tied to poor case detection, underfunding and erratic drug this grim reality, the country has set an ambitious goal. It aims to eliminate TB by the end of 2025, five years ahead of the global target set by the World Health Organization (WHO) and United Nations member as defined by the WHO, means cutting new TB cases by 80% and deaths by 90% compared with 2015 visits to TB centres in Delhi and the eastern state of Odisha revealed troubling gaps in the government's TB Odisha's Khordha district, around 30km (18.6 miles) from state capital Bhubaneshwar, 32-year-old day-labourer Kanhucharan Sahu is struggling to continue his two-year-old daughter's TB treatment, with government medicines unavailable for three months and private ones costing 1,500 rupees a month - an unbearable burden."We can't see her suffer anymore," he says, his voice breaking. "We even thought of abandoning her."At Odisha's local TB office, officials promised to review Sahu's case, but a staffer admitted, "We rarely get the medicines we need, so we ration them." Mr Sahu says he hasn't received the promised 1,000 rupees monthly support from the federal government and at the local TB office, officials admit to chronic shortages, leaving families like his adrift in a failing Routray, who runs the patient support group Sahyog, says medicine shortages are now routine, with government outlets often running dry. "How can we talk about ending TB with such gaps?" she are other hurdles too - for example, changing treatment centres involves navigating complex bureaucracy, a barrier that often leads to missed doses and incomplete care. This poses a major hurdle for India's vast population of migrant a hospital near Khordha, 50-year-old Babu Nayak, a sweeper who was diagnosed with TB in 2023, struggles to continue his treatment. He was regularly forced to travel 100km to his village for medicines as officials insisted he collect them from the original centre where he was diagnosed and first treated. "It became too difficult," he to travel so often, Mr Nayak stopped taking the medication altogether."It was a mistake," he admitted, after contracting TB again last year and being his hospital, no TB specialist was available, highlighting another critical gap in India's fight: a shortage of frontline health BBC shared its findings with the federal health ministry and officials in charge of the TB programme in Delhi and Odisha. There was no response despite repeated reminders.A 2023 parliamentary report showed there were many vacant roles across all levels of the TB programme, affecting diagnosis, treatment and follow-up - especially in rural and underserved vaccines help India triumph over tuberculosis?In 2018, when Prime Minister Narendra Modi brought forward India's TB elimination target to 2025, he cited the government's intensified efforts as a reason for optimism. Two years later, the Covid pandemic disrupted TB elimination efforts globally, delaying diagnosis, diverting resources and pausing routine services. Medicine shortages, staff constraints and weakened patient monitoring have further widened the gap between ambition and these challenges, India has made some the past decade, the country has reduced its tuberculosis-related mortality. Between 2015 and 2023, TB deaths declined from 28 to 22 per 100,000 people. This figure, however, is still high when compared with the global average which stands at number of reported cases has gone up, which the government credits to its targeted outreach and screening programmes. In 2024, India recorded 2.6 million TB cases, up from 2.5 million in 2023. Federal Health Minister JP Nadda recently touted innovations like handheld X-ray devices as game-changers in expanding testing. But on the ground, the picture is less optimistic."I still see some patients come to me with reports of sputum (phlegm) smear microscopy for TB, a test which has a much lower detection rate as compared to genetic tests," says Dr Lancelot Pinto, a Mumbai-based tests, which includes RT-PCR machines - widely used to diagnose HIV, influenza and most recently, Covid-19 - and Nucleic Acid Amplification Testing, also examine the sputum sample but with greater sensitivity and in a shorter the tests can reveal whether the TB strain is drug-resistant or sensitive, something that microscopic testing can't do, Dr Pinto gap, he adds, stems not just from lack of awareness but from limited access to modern tests."Genetic testing is free at government hospitals but not uniformly available, with only a few states being able to provide it."In May, Modi led a high-level review of India's TB elimination programme, reaffirming the country's commitment to defeating the the official statement notably skipped mention of the 2025 deadline. Instead, it highlighted community-driven strategies - better sanitation, nutrition and social support for TB-affected families - as key to the government has also prioritised better diagnosis, treatment and prevention at the core of its elimination approach mirrors the WHO's view of TB as a "disease of poverty". In its 2024 report, WHO chief Tedros Adhanom Ghebreyesus called it "the definitive disease of deprivation", noting how poverty, malnutrition and treatment costs trap patients in a vicious cycle. As India pushes toward its goal of eliminating the disease, deep health and social inequalities remain just six months left until India's self-imposed deadline, new complications have fallout from US President Donald Trump's withdrawal from the WHO and suspension of USAID operations has raised concerns about future funding for global TB efforts. Since 1998, USAID has invested more than $140m to help diagnose and treat TB patients in India. However, India's federal health secretary insists there is "no budgetary problem" hope lies on the horizon. Sixteen TB vaccine candidates are currently in development across the world, with the WHO projecting potential availability within five years, pending successful trials.
The Guardian
6 hours ago
- The Guardian
UnitedHealth faces federal scrutiny into whistleblower claims
US lawmakers on both sides of the aisle are raising concerns and seeking investigations in the wake of Guardian reporting on whistleblower claims about practices within UnitedHealth Group's nursing home partnership programs. One US senator has announced he is launching an investigation and two US representatives are now calling on the US Department of Justice to expand its reported investigations of the nation's largest healthcare conglomerate. Others said they are troubled by whistleblower allegations reported by the Guardian – including claims that UnitedHealth paid bonuses to nursing homes to help reduce residents' hospital transfers and used improper sales tactics to get nursing home residents to sign up for the company's Medicare Advantage plans. Two Democratic members of Congress – representatives Alexandria Ocasio-Cortez of New York and Lloyd Doggett of Texas – filed a letter on Monday that urges the Department of Justice to 'thoroughly review new revelations from investigative reporting and whistleblower complaints, which suggest that UnitedHealth may have engaged in illegal activities'. 'The Guardian's findings reveal the need for a wide-ranging investigation by the Department of Justice into years, if not decades, of potential waste, fraud, and abuse at UnitedHealth,' the letter read. The lawmakers are demanding a briefing on current and planned investigations by 14 July. UnitedHealth vigorously denies the whistleblowers' allegations and says the Guardian's reporting on these issues is 'blatantly false and misleading'. In response to a question about the two representatives' letter, the company said the Department of Justice 'has already declined to pursue the matter' – a reference to the agency's previous decisions not to intervene in two whistleblower lawsuits against UnitedHealth filed under the US False Claims Act. One of those lawsuits was ultimately dropped and the other is pending in federal court in Georgia. Another Democrat, the Oregon senator Ron Wyden, announced last month on X that his office was 'launching a full investigation to verify these whistleblower accounts'. 'This reporting demands further inquiry – nobody deserves to have their medical care jeopardized to pad insurance company profits,' Wyden, the ranking member of the Senate's finance committee, said. 'My staff on the Finance Committee have a decade-long record of thorough and objective investigations that follow the facts towards solutions that improve federal health care policy for all Americans.' Senator Josh Hawley, a Missouri Republican who sits on the Senate investigations subcommittee, said it is 'alarming to hear these serious allegations' about the company's practices. 'I look forward to securing justice for patients, policyholders and whistleblowers alike who've been harmed by insurance companies.' Another Republican, Georgia representative Buddy Carter, expressed similar concerns. 'If these allegations are true, UnitedHealth must be held responsible for their gross abuse of patients,' Carter, chair of the House subcommittee on health, said in a statement. 'Patients should always come before profits.' Senator Richard Blumenthal of Connecticut, ranking member of the Senate investigations subcommittee, said the 'courage and conviction' of the whistleblowers will serve as 'an impetus for reform. Shining a light on abuses of consumer trust is a call to action – and a demand for accountability.' UnitedHealth says its partnerships with nursing homes ensure better care for seniors 'through on-site clinical care, personalized treatment plans, and enhanced coordination among caregivers'. The company says these arrangements have been highly successful in helping nursing homes prevent unnecessary hospital stays that can lead to serious issues such as delirium, falls, pressure injuries and 'sometimes even fatal consequences'. Two whistleblowers who worked for UnitedHealth as nurse practitioners submitted sworn declarations in May alleging that the company had used improper tactics to reduce hospital transfers for ailing nursing home residents. Their declarations were submitted to the Securities and Exchange Commission (SEC), the Federal Trade Commission (FTC), the Washington state attorney general's office and Congress, according to Whistleblower Aid, the non-profit assisting both nurse practitioners. Whistleblower Maxwell Ollivant's declaration, first reported on by the Guardian in May, says he witnessed UnitedHealth 'delay and deny medically necessary emergency care' to vulnerable nursing home residents in order to 'retain more money' from the payments that the company was receiving from the US government's Medicare Advantage program. Under Medicare Advantage, a private alternative to traditional Medicare, the federal government pays insurers a fixed sum to cover seniors' medical services. The less insurers spend on covering medical expenses, the more in public dollars they have left over. Ollivant's declaration alleges that UnitedHealth 'actively avoided medically necessary hospitalizations – hospitalizations in serious life-threatening situations, or situations to avoid imminent death or incredibly catastrophic results – to keep their costs down, and drove vulnerable patients toward signing Do Not Resuscitate (DNRs) and Do Not Hospitalize orders to avoid providing hospital services for life threatening illnesses'. UnitedHealth noted that the Department of Justice declined to join the lawsuit that Ollivant filed against the company and later dropped. The company said Ollivant 'is not in a position to assess the effectiveness of our programs – he lacks both the necessary data and the expertise'. The second whistleblower, whose declaration was filed anonymously, worked with UnitedHealth for several years. Her declaration says her experiences as a nurse practitioner within its nursing home programs gave her 'first-hand insight into the evolution and impact of substandard care practices resulting from the training, culture, processes and bonus system of delays and denials of medically necessary care'. That declaration criticizes the company's '[a]ggressive [p]ush for DNRs' and says 'the decision to receive life-saving care should rest with the patient or their legal representative, not myself, and certainly not the insurance company'. UnitedHealth said the allegations in the anonymous whistleblower's declaration show she 'did not fully understand our clinical model' and that her perspective 'does not reflect the dedication and excellence of the many outstanding clinicians who understand the impact they have in supporting their patients and improving health outcomes'. The company also denies the claims regarding DNRs. 'At no time have we encouraged or pushed' nursing home residents 'to sign a DNR directive', a UnitedHealth representative said. 'Our health care providers are ethically bound to respect patient autonomy and support informed decision-making without coercion.' The Guardian's previous reporting also references allegations relating to the legal claims of a third whistleblower, Brook Gonite, a former salesperson for UnitedHealth's nursing home program. Gonite alleges in a lawsuit in federal court in Georgia that UnitedHealth wrongly solicited and enrolled vulnerable, elderly patients for its nursing home programs through improper marketing tactics, including violations of Hipaa, the federal medical privacy act, and paid kickbacks to nursing homes to obtain illegal referrals of their residents. UnitedHealth denied those allegations and moved to dismiss Gonite's lawsuit. The Department of Justice, which declined to formally intervene in the case, opposed UnitedHealth's motion to dismiss. In April, federal judge Marc Treadwell denied UnitedHealth's motion to dismiss, finding that Gonite's lawsuit puts forth 'substantial and concerning' factual allegations that 'plausibly' assert violations of federal protections meant to ensure vulnerable nursing home residents can make informed decisions about their medical care. The company continues to deny those claims and says Gonite was fired for engaging in illegal sales tactics similar to those alleged in his suit. In a statement, the company said its employees 'are trained on compliant interactions with nursing home staff and nursing home residents, in accordance with the Medicare Marketing Guidelines and other applicable laws'. Last week, shortly before the Guardian was to publish a second story providing additional detail about Gonite's pending lawsuit and the other two whistleblowers' declarations, UnitedHealth filed a lawsuit against the Guardian in Delaware state court, claiming the allegations were false and libelous. In a statement, the company said 'the article published by The Guardian is not only riddled with inaccuracies – it is so blatantly false and misleading that we have filed a defamation lawsuit to hold the publication accountable and bring the full truth to light'. The Guardian has said it stands by its 'deeply sourced, independent reporting, which is based on thousands of corporate and patient records, publicly filed lawsuits, declarations submitted to federal and state agencies, and interviews with more than 20 current and former UnitedHealth employees – as well as statements and information provided by UnitedHealth itself over several weeks'.
